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Background: The deleted in liver cancer 1 (DLC1) and plasminogen activator inhibitor 1 (PAI-1) are known to be
closely associated with tumor growth and metastasis in several kinds of human tumors. The aim of this study was
to investigate the expression of DLC1 and PAI-1 in ovarian carcinoma, and evaluate their relations with the
prognosis of ovarian carcinoma.
Methods: Immunohistochemical staining and Western blot were used to examine the expressions of DLC1 and
PAI-1 protein in 25 specimens normal ovarian tissues, 52 specimens of serous cystadenocarcinoma tissues and 23
specimens of mucinous cystadenocarcinoma tissues. Chi-square test, Logistic regression and Partial Correlate
analysis were performed to evaluate the association between DLC1 and PAI-1 with clinicopathological
characteristics. Overall survival was estimated by Kaplan-Meier curves and multivariate Cox analysis. The
relationships between DLC1 and PAI-1 protein expression were analyzed by Pearson’s correlation coefficient.
Results: The expression of DLC1 protein in ovarian carcinoma tissues was significantly lower than that in normal
ovarian tissues, but it was converse for PAI-1. In ovarian carcinoma, the expression of DLC1 was significantly
associated with advanced FIGO stage, ascites and positive lymph node metastasis, whereas PAI-1 protein was
closely related with advanced FIGO stage, poor histological differentiation and lymph node metastasis. The
expression of DLC1 was negatively correlated with PAI-1 in ovarian carcinoma. Ovarian cancer patients with
negative expression of DLC1 and positive expression of PAI-1 had the worst overall survival time compared to other
patients.
Conclusions: The expression of DLC1 and PAI-1 were closely related with the metastasis and invasion of ovarian
carcinoma, only the combination of DLC1 and PAI-1 could serve as an independent prognostic factor of ovarian
carcinoma.
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PrognosisBackground
Epithelial ovarian cancer (EOC) is the leading cause of
cancer-related death in women diagnosed with gyneco-
logic malignancies [1]. The reported 5-year survival rates
for women with EOC are only 25% ~ 30%, in spite of re-
cent advances in cytoreductive surgery and chemothera-
peutic agents. Recent advances in histopathology and* Correspondence: hrshi2011@163.com
1Department of Obstetrics and Gynecology, the First Affiliated Hospital of
Zhengzhou University, NO.1 Jian She Road, Zhengzhou 450052, China
Full list of author information is available at the end of the article
© 2013 Ren et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orcytogenetics have provided insights into pathophysio-
logic features and natural history of EOC [2,3].
Deleted in liver cancer 1 (DLC1), a GTPase-activating
protein (GAP) domain containing tumor suppressor
which localizes at focal adhesions, is considered as a po-
tential tumor suppressor for many malignant tumors [4].
DLC1 is a focal adhesion molecule that plays a role in
preventing cell transformation in the liver as well as
many other tissues [5,6]. Using gene transfection tech-
nology, DLC-1 gene high expression can inhibit the
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is the key inhibitor of the plasminogen activation system
(PAS), PAI-1 participate in the pathophysiology of a num-
ber of diseases such as atherosclerosis, restenosis, and
cancer [8-11]. The canonical view of PAI-1 as an inhibitor
of tPA and uPA cannot fully account for a mechanism
whereby PAI-1 contributes to the disease. As an effective
specific uPA inhibitor, PAI-1 participated in the formation
of uPA/uPAR/PAI-1 complexes, the regulation of uPA ac-
tivity and the position of uPA receptor on the cell mem-
brane. By this means, PAI-1 maintained the balance of the
extracellular protein degradation and prevented the exces-
sive degradation of ECM, thus inhibited tumor metastasis
[12,13]. In ovarian cancer cell lines, cell migratory and in-
vasive phenotype is reduced by active PAI-1 due to its
ability to inhibit plasminogen activation compared to their
plasminogen activator system profiles [14].
In normal prostate epithelial cells, silencing of DLC1
by RNAi can upregulate PAI-1 expression and reduce
cell migration [15]. However, the relations between the
expression of DLC1 and PAI-1 and invasion, metastasis
and prognosis of epithelial ovarian carcinoma were still
unknown. In this study, we detected the expression of
DLC1 and PAI-1 in ovarian carcinoma, evaluated the as-
sociations between their expressions and clinical patho-
logic factors, and explored the role of DLC1 and PAI-1
in the prognosis of epithelial ovarian carcinoma.
Material and methods
Patients and tissue samples
100 ovarian specimens were obtained from the patients
during surgeries in the Department of gynaecology and
obstetrics, the First Affiliated Hospital of Zhengzhou
University (from January 2007 to October 2010), which
consisted of 25 specimens normal ovarian tissues
(obtained from patients who underwent hysterectomy
and oophorectomy for multiple uterinemyoma other
than ovarian tumors), 75 specimens of ovarian carcin-
oma tissues (contains 52 serous cystadenocarcinoma and
23 mucinous cystadenocarcinoma). Every I-II stage EOC
patient underwent satisfy cytoreductive surgery, every III-
IV stage EOC patient underwent unsatisfy cytoreductive
surgery. The tissue samples were collected after surgery
resection immediately and saved in liquid nitrogen
promptly. The median age of all the patients was
52 years old (range 19 to 73). All patients did not re-
ceive preoperative radiochemotherapy. The median
follow-up was 36 months (range 9 to 70 months), 48
patients were still survival at the end of follow-up. The
tissue sample collection all obtained the consent of en-
rolled patients before the operation, and the present
study was approved by the local Ethics Committee of
Zhengzhou University. The collecting of tissue samples
was supervised by a pathologist, and all the tissuesamples were verified by two pathologists before IHC
independently by HE stain.
Immunohistochemistry
The antibodies used in the Immunohistochemistry, fol-
lowing manufacturer’s protocols, were anti-DLC1 and
anti- PAI1 (Santa Cruz, USA). Immunohistochemistry
staining used DAKO EnVision System (Dako Diagnostics,
Switzerland) following the protocol. For DLC1 and PAI-1
protein, staining localized in the cytoplasm was consid-
ered positive. The immunoreactive score was calculated
followed Remmele’s method [16]. The percentage of posi-
tive cells was scored as follows: without stain scored - (0),
less than 10% positive cells scored + (1), 10–50% ++ (2),
51–80% +++ (3) and more than 80% ++++ (4). The stain-
ing intensity was also scored on a four-tiered scale (nega-
tive scored 0, low intensity positive staining 1, moderate
intensity positive staining 2, and strong intensity positive
staining 3). The staining intensity score plus the positive
cell score is the overall score. 0 score was negative staining
(−), more than 2 scores were positive staining (+), more
than 6 scores was strong positive (++). Immunoreactive
score was performed by two pathologists independently.
Western blotting
The antibodies used in the Western blot, following manu-
facturer’s protocols, were anti-DLC1, anti-PAI-1 and anti-
β-actin (Santa Cruz, USA). Tissue lysates containing equal
amounts of total protein were separated by SDS-PAGE.
To detect proteins of interest, enhanced chemilumines-
cence system was used according to the supplier’s proto-
col (Lumi-Light Western Blotting substrate; Roche).
Relative levels of proteins were estimated densitometric-
ally using β-actin as internal reference.
Statistical analysis
SPSS 17.0 software was used for the statistical analysis.
Continuous variables were expressed as X  s. Chi-square
test, Logistic regression analysis and Partial Correlate were
performed to evaluate the association between DLC1 and
PAI-1 with clinicopathological characteristics. Overall sur-
vival was estimated by Kaplan-Meier curves and multi-
variate Cox analysis. The relationships between DLC1 and
PAI-1 protein expression were analyzed by Pearson’s cor-
relation coefficient. Results were considered statistically
significant when P less than 0.05.
Results
Expression of DLC1 and PAI-1 in epithelial ovarian cancer
tissues and normal ovarian tissues
Positive staining for DLC1 observed in malignant and
normal ovarian tissues were 33/75 (44.0%) and 25/25
(100.0%) respectively, but were 51/75 (68.0%) and 9/25
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showed that the expression of DLC1 protein in normal
and malignant ovarian tissues were (0.984 ± 0.010) and
(0.497 ± 0.028), but (0.341 ± 0.019) and (0.718 ± 0.017)
for PAI-1 (Figures 3 and 4). The expression of DLC1 in
ovarian carcinoma tissues was significantly lower than
that in normal ovarian tissues (P < 0.05), whereas it was
converse for PAI-1.
Association of DLC1 and PAI-1 expression with the
clinicopathologic characteristics of ovarian cancer
As shown in Table 1, the expression of DLC1 and PAI-1
were significantly associated with FIGO stage and lymph
node metastasis in ovarian carcinoma. In addition,
DLC1 was also related with ascites, and PAI-1 was re-
lated with histological differentiation.
The correlation between DLC1 and PAI-1 in epithelial
ovarian carcinoma
Among the 75 specimens of EOC, there were 15 positive
for DLC1 and negative for PAI-1, as well as 33 negative
for DLC1 and positive for PAI-1. This result suggests a
negative correlation between the expression of DLC1
and PAI-1 (r = −0.256, P = 0.027).
Associations of DLC1 and PAI-1 expression with the
prognosis of ovarian cancer
Partial Correlate analysis showed the expression of DLC1
was negatively related with FIGO stage (P = 0.015), asci-
tes (P = 0.043), lymph node metastasis (P = 0.021), butFigure 1 Positive expression of DLC1 and PAI-1 in different ovarian ti
cells showed a higher staining of DLC1 (Up-left), but ovarian cancer cells sh
lower staining of PAI-1 (Down-left), but ovarian cancer cells showed higher
performed followed Remmele’s method, the number of positive-staining c
percentage of positive cells was calculated (DAB staining, ×400).positively related with prognosis (P = 0.009). The ex-
pression of PAI-1 was positively related with FIGO
stage (P = 0.011), histological differentiation (P = 0.036),
lymph node metastasis (P = 0.027), but negatively re-
lated with prognosis (P = 0.018). Logistic Regression
analysis indicated the expression of DLC1 was closely
related with FIGO stage (P = 0.032), the expression of
PAI-1 was closely related with lymph node metastasis
(P = 0.048), and the expression of DLC1 combined with
PAI-1 were significant correlative factors with prognosis
(P < 0.05). Furthermore, Kaplan-Meier survival curves
demonstrated that ovarian cancer patients with negative
expression of DLC1 and positive expression of PAI-1 had
the worst overall survival time compared to other patients
(Figure 5). Multivariate Cox analysis showed that only
DLC1 combined with PAI-1 expression (P < 0.05) were in-
dependent risk factors of prognosis.
Discussion
Invasion and metastasis are characteristics of malignant
solid tumors, and many mechanisms are involved in
these processes. Advanced FIGO stage, ascites and posi-
tive lymph node metastasis are the critical factors in the
invasion and metastatic spread of ovarian cancer
[3,17,18]. Furthermore, they are related with prognosis
in patients with ovarian cancer. However, the mechan-
ism of the invasion and metastasis events in ovarian can-
cer has yet to be defined.
DLC1 was expressed in many normal tissues, but its
expression was lost or down regulated in various cancersssues detected by immunohistochemistry staining. Normal ovary
owed lower density staining (Up-right); normal ovary cells showed a
density staining (Down-left). Immunoreactive Score method
ells in 10 representative microscopic fields was counted, and the
Figure 2 The immunoreactive scores of DLC1 and PAI-1 in different ovarian tissues detected by immunohistochemistry staining.
Normal ovary showed a higher score of DLC1, but ovarian cancer showed lower score, significant differences were observed (P < 0.05); normal
ovary showed a lower score of PAI-1, but ovarian cancer showed higher score, significant differences were observed (P < 0.05). Bar graphs show
the positive score of DLC1 and PAI-1 protein.
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prostate cancers, which suggested that DLC1 may func-
tion as a tumor suppressor [6,19-22]. Re-expression of
DLC1 in liver, breast, lung cancer cell lines inhibits can-
cer cell growth [23]. Likewise, reintroduction of DLC1
breast cancer cell lines results decreased tumorigenic
growth, supporting its major role as a tumor suppressor
[24,25]. However, tumor malignant transformation and
progression to metastasis are often associated with
changes in cell cytoskeletal organization and cell-cell ad-
hesion. DLC1 gene can encode a RhoGAP protein that
inactivates Rho GTPases, which are critically involved in
the regulation of cytoskeleton and cell migration [4,26].
Recently, abnormal, low, or lack of DLC1 expression wasFigure 3 Expression of DLC1 and PAI-1 in normal ovarian tissue
(A) and ovarian cancer tissues (B) detected by Western Blotting.
Interest bands were presented by Western Blotting from different
tissue samples, each protein band represents one random specimen
tissue. Normal ovary showed a higher expression of DLC1, but ovarian
cancer showed lower expression; normal ovary showed a lower
expression of PAI-1, but ovarian cancer showed higher expression.found to be associated with the metastasis of breast and
hepatocellular cancers, suggesting that DLC1 plays an
important role not only in tumorigenesis but also in me-
tastasis [5,27]. The gene expression profiles of metastatic
and non-metastatic sublines of the parental MDA-MB-435
breast cancer cell line were compared and DLC1 was
down-expressed in the metastatic subline. Restoration of
DLC1 in metastatic cell line leads to the inhibition of mi-
gration and invasion in cell culture assays and a significant
reduction in metastases in nude mouse experiments [27].
In present study, although expression of DLC1 was ob-
served in ovarian carcinoma tissues, it was significantly
lower than that in normal ovarian tissues. The expression
of DLC1 was significantly associated with advanced FIGO
stage, ascites, and positive lymph node metastasis, which
suggested that DLC1 might be involved in the invasion
and metastasis of ovarian cancer.
Plasminogen activator inhibitor-1 (PAI-1) belongs to
the serine protease inhibitor superfamily, previous stud-
ies about PAI-1 mainly focused on the inhibition of fi-
brinolysis [7,13,28,29]. Recently, it has been found that
PAI-1 is involved in the pathophysiological process
about degradation of extracellular matrix, cell migration,
metastasis and various reactions of cellular signal trans-
duction [8,30,31]. In a retrospective study, a strong asso-
ciation between elevated levels of PAI-1 and aggressive
disease recurrence has been found [32]. Elevated expres-
sion of PAI-1 protein was associated with increased risk
of distant metastasis in renal cancer [33,34]. High PAI-1
Figure 4 Bar graph of the Western Blotting assay. Each bar represents the relative value of DLC1 and PAI-1 protein, significant differences
were observed between normal ovary and ovarian carcinoma (P < 0.05).
Table 1 Relations between expression of DLC1 and PAI-1 in ovarian cancer and clinical characteristics of epithelial
ovarian cancer
Group n DLC1 χ2 P PAI-1 χ2 P
+ % + %
Age
<50 27 11 40.7 0.182 0.670 20 74.1 0.715 0.398
≥50 48 22 45.8 31 64.6
Histological type
Serous 52 21 40.4 0.900 0.343 35 67.3 0.037 0.847
Mucinous 23 12 52.2 16 69.6
FIGO stage
I ~ II 32 19 59.4 5.355 0.021* 16 50.0 8.311 0.004*
III ~ IV 43 14 32.6 35 81.4
Histological differentiation
G1 16 9 56.3 5.372 0.068 7 43.8 6.359 0.042*
G2 25 14 56.0 17 68.0
G3 34 10 29.4 27 79.4
Lymph metastasis
YES 33 9 27.3 6.692 0.010* 28 84.8 7.688 0.006*
NO 42 24 57.1 23 54.8
Ascites
YES 52 17 32.7 8.799 0.003* 37 71.2 0.775 0.379
NO 23 16 69.6 14 60.9
*Chi-square test. Compared with normal ovarian tissues P < 0.05.
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Figure 5 Survival curves showing the association between overall survival and combining DLC1 and PAI-1 expression. Ovarian cancer
patients with negative expression of DLC1 and positive expression of PAI-1 had the worst overall survival time compared to other patients.
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PAI-1 is a strong predictor of local, as well as distant me-
tastasis [35]. The positive rates of PAI-1 was significantly
higher in epithelial ovarian cancer than in benign ovarian
tumor which was detected by immunohistochemistry, and
PAI-1 was an independent factor for overall survival [36].
PAI-1 was significantly overexpressed in the tumor epithe-
lium of ovarian cancer in comparison to the ovarian epi-
thelium of benign ovarian tumor and normal ovary, which
was detected by immunohistochemistry and ELISA [37].
These studies suggested that PAI-1 might play an import-
ant role in the invasion and metastasis of solid tumors. In
this study, western blot and immunohistochemistry ana-
lysis showed high PAI-1 protein levels in ovarian carcin-
oma tissues, which was significantly higher than that in
normal ovarian tissues. We also found that the expression
of PAI-1 protein were significantly associated with ad-
vanced FIGO stage, poor histological differentiation and
lymph node metastasis, suggesting that PAI-1 was impli-
cated in the invasion and metastasis of ovarian cancer.
However, the interaction mechanisms of DLC1 and
PAI-1 that involve in the invasion and metastasis in
tumor cells had not been well studied. Recently, in nor-
mal prostate epithelial cells DLC1 modulates the expres-
sion of PAI-1, which is a negative regulator for cell
migration, in a GAP domain and EGFR-MEK-dependent
manner was demonstrated [15]. While, independent of
PAI-1, the interaction of DLC1 with tensin members
positively regulates cell migration. In our study, the ex-
pression of DLC1 and PAI-1 in ovarian carcinoma tis-
sues showed an obvious negative correlation, whichindicated DLC1 and PAI-1 might be closely related to
the tumorigenesis of ovarian carcinoma, and linked in
the progress of tumor invasion and metastasis.
In Partial Correlate analysis, the expression of DLC1
and PAI-1 were closely related with the metastasis and
invasion of ovarian carcinoma, both DLC1 and PAI-1
could be used to assess the prognosis respectively, but
only the combination of DLC1 and PAI-1 was an inde-
pendent prognostic factor of ovarian carcinoma which
was confirmed by Logistic Regression analysis. As the
survival analysis data shown in Figure 5, patients with
low expression of DLC1 or high expression of PAI-1
both had reduced survival time, especially when DLC1
was low expression and PAI-1 was high expression at
the same time. Those results strengthened the notion
that combination of DLC1 and PAI-1 could serve as an
independent prognostic factor of ovarian carcinoma.Conclusions
The enrolled samples were limited, and the follow-up
time was varying, but this study presented some valuable
results. Upon the present results, the expression of
DLC1 and PAI-1 were closely related with the metastasis
and invasion of ovarian carcinoma, both DLC1 and PAI-
1could be used to assess the prognosis respectively, but
only the combination of DLC1 and PAI-1 could serve as
an independent prognostic factor of ovarian carcinoma.
In next steps, the potential signaling pathways that regu-
late DLC1 and PAI-1 expression in ovarian cancer cell
migration and invasion will be discussed.
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